3-Aryl-2-{4-[4-(2,4-dioxothiazolidin-5-ylmethyl)phenoxy]-phenyl}-acrylic acid alkyl ester: Synthesis and antihyperglycemic evaluation

Medicinal Chemistry Research

Volumn 20, Issue 6, 2011, Pages 678-686

  Kumar, Ashwani ^a   Chawla, Amit ^a   Jain, Sandeep ^a   Kumar, Parvin ^a   Kumar, Sunil ^b  

^a GURU JAMBHESHWAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

^b Guru Nanak Khalsa College   (India)

Author keywords

2,4 Thiazolidinedione; Antihyperglycemic activity; Neonatal streptozotocininduced diabetic rats; PPARc

Indexed keywords

3 (2,4 DIMETHOXYPHENYL) 2 [4 [4 (2,4 DIOXOTHIAZOLIDIN 5 YLMETHYL)PHENOXY]PHENYL]ACRYLIC ACID METHYL ESTER; ACRYLIC ACID ETHYL ESTER; ANTIDIABETIC AGENT; CINNAMIC ACID DERIVATIVE; GLUCOSE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; MALE; NEWBORN; NONHUMAN; PHYSICAL CHEMISTRY; RAT; STREPTOZOCIN DIABETES; STRUCTURE ACTIVITY RELATION;

EID: 80052031472     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-010-9369-3     Document Type: Article

References (30)

1. Acton JJ, Black RM, Jones AB, Moller DE, Colwell L, Doebber TW, MacNaul KL, Berger J, Wood HB (2005) Benzoyl 2-methyl indoles as selective PPAR c modulators. Bioorg Med Chem Lett 15:357-362 (Pubitemid 39647150)
2. Adisakwattana S, Roengsamran S, Hsu WH, Yibchok-anun S (2005) Mechanisms of antihyperglycemic effect of p-methoxycinnamic acid in normal and streptozotocin-induced diabetic rats. Life Sci 78:406-412 (Pubitemid 41597550)
3. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD (1996) Thiazolidinediones produce a conformational change in peroxisomal proliferators activated receptor-gamma binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137:4189-4195 (Pubitemid 26321865)
4. Bhat BA, Ponnala S, Sahu DP, Tiwari P, Tripathi BK, Srivastava AK (2004) Synthesis and antihyperglycemic activity profiles of novel thiazolidinedione derivatives. Bioorg Med Chem 12:5857-5864 (Pubitemid 39388184)
5. Bjork S, Kapur A, King H, Nair J, Ramachandran A (2003) Global policy: aspects of diabetes in India. Health Policy 66:61-72 (Pubitemid 37123024)
6. Brooks DA, Etgen GJ, Rito CJ, Shuker AJ, Dominianni SJ, Warshawsky AM, Ardecky R, Paterniti JR, Tyhonas J, Karanewsky DS, Kauffman RF, Broderick CL, Oldham BA, Rafizadeh CM, Winneroski LL, Faul MM, McCarthy JR (2001) Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy} propionic acids: a new class of dual PPARa/c agonists. J Med Chem 44:2061-2064 (Pubitemid 32861765)
7. Cantello BC, Cawthorne MA, Cottam GP, Duff PT, Haigh D, Hindley RM, Lister CA, Smith SA, Thurlby PL (1994) [[x9-(Heterocyclylamino) alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem 37:3977-3985 (Pubitemid 24379687)
8. Chittiboyina AG, Venkatraman MS, Mizuno CS, Desai PV, Patny A, Benson SC, Ho CI, Kurtz TW, Pershadsingh HA, Avery MA (2006) Design and synthesis of the first generation of dithiolane thiazolidinedione and phenylacetic acid-based PPARgamma agonists. J Med Chem 49:4072-4084 (Pubitemid 44036654)
9. Duendar OB, Uenluesoy MC, Verspohl EJ, Ertan R (2006) Synthesis and antidiabetic activity of novel 2,4-thiazolidinedione derivatives containing a thiazole ring. Chem Inform 56:621-625 (Pubitemid 44521097)
10. Dundar OB, Verspohl EJ, Evcimen ND, Kaup RM, Bauer K, Sar?kaya M, Evranos B, Ertan R (2008) Synthesis and biological activity of some new flavonyl-2,4-thiazolidinediones. Bioorg Med Chem 16:6747-6751
11. Ebdrup S, Pettersson I, Rasmussen HB, Deussen HJ, Jensen AF, Mortensen SB, Fleckner J, Pridal L, Nygaard L, Sauerberg P (2003) Synthesis and biological and structural characterization of the dual-actingp peroxisome proliferator-activated receptor c/a agonist Ragaglitazar. J Med Chem 46:1306-1317 (Pubitemid 36512696)
12. Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science 240:889-895
13. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W (2006) From molecular action to physiological outputs: peroxisome proliferators activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45:120-159 (Pubitemid 43248732)
14. Hara T, Hirayama F, Arima H, Yamaguchi Y, Uekama K (2006) Improvement of solubility and oral bioavailability of 2-(Ncyanoimino)-5-{(E)-4- styrylbenzylidene}-4-oxothiazolidine (FPFS-410) with antidiabetic and lipid-lowering activities in dogs by 2-hydroxypropyl-b-cyclodextrin. Chem Pharm Bull 54:344-349
15. Hardman JG, Limbirol LE, Gilman AG, (2007) Goodman & Gilman's the pharmacological basis of therapeutics, 10th edn. McGraw Hill, Inc., New York, pp 1679-1707
16. Henke BR, Adkison KK, Blanchard SG, Leesnitzer LM, Mook RA, Plunker KD, Ray JA, Roberson C, Unwalla R, Willson TM (1999) Synthesis and biological activity of a novel series of indole derived PPARc agonists. Bioorg Med Chem Lett 9:3329-3334
17. Imoto H, Imamiya E, Momose Y, Sugiyama Y, Kimura H, Sohda T (2002) Studies on non-thiazolidinedione antidiabetic agents-discovery of novel oxyiminoacetic acid derivatives. Chem Pharm Bull 50:1349-1357 (Pubitemid 41702035)
18. John R, White R, Keith C (2003) Type 2 diabetes and insulin resistance: counseling patients in the pharmacy. US Pharm 28:4-6
19. Koyama H, Boueres JK, Han W, Metzger EJ, Bergman JP, Gratale DF, Miller DJ, Tolman RL, MacNaul KL, Berger JP, Doebber TW, Leung K, Moller DE, Hecka JV, Sahoo SP (2003) 5-Arylthiazolidine-2,4-diones as selective PPARc agonists. Bioorg Med Chem Lett 13:1801-1804
20. Kuhn B, Hilpert H, Benz J, Binggeli A, Grether U, Humm R, Marki HP, Meyer MMP (2006) Structure-based design of indole propionic acids as novel PPARa/c co-agonists. Bioorg Med Chem Lett 16:4016-4020 (Pubitemid 43903212)
21. Lee HW, Kim BY, Ahn JB, Kang SK, Lee JH, Shin JS, Ahn SK, Lee SJ, Yoon SS (2005) Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. Eur J Med Chem 40:862-874 (Pubitemid 41376301)
22. Liu KG, Lambert MH, Leesnitzer LM (2001) Identification of a series of PPARc/d dual agonists via solid-phase parallel synthesis. Bioorg Med Chem Lett 11:2959-2962 (Pubitemid 33000105)
23. Luna B, Mark N (2001) Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician 63:1747-1780
24. Madhavan GR, Chakrabarti R, Vikramadithyan RK, Rao NVSM, Balraju V, Rajesh BM, Misra P, Kumar SKB, Lohray BB, Lohray VB, Rajagopalan R (2002) Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives. Bioorg Med Chem 10:2671-2680 (Pubitemid 34626230)
25. Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N (2008) Pioglitazone and cardiovascular risk: a comprehensive meta-analysis of randomized clinical trials. Diab Obes Metab 10:1221-1238
26. Nomura M, Kinoshita S, Satoh H, Maeda T, Murakami K, Tsunoda M, Miyachi H, Awano K (1999) (3-Substituted Benzyl) thiazolidine-2,4-diones as structurally new antihyperglycemic agents. Bioorg Med Chem Lett 9:533-538 (Pubitemid 29090646)
27. Prabhakar C, Madhusudhan G, Sahadev K, Reddy CM, Sarma MR, Reddy GO, Chakrabarti R, Rao CS, Kumar TD, Rajagopalan R (1998) Synthesis and biological activity of novel thiazolidinediones. Bioorg Med Chem Lett 8:2725-2730 (Pubitemid 28496660)
28. Staels B, Fruchart JC (2005) Therapeutic roles of peroxisome proliferators activated receptor agonists. Diabetes 54:2460-2470 (Pubitemid 41134276)
29. Susman JL, Helseth LD (1997) Reducing the complications of type II diabetes: a patient-centered approach. Am Fam Physician 56:471-480
30. Zhang BB, Moller DE (2000) New approaches in the treatment of type 2 diabetes. Curr Opin Chem Biol 4:461-467 (Pubitemid 30621049)